That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

Pharmaceutical firm Gilead has admitted paying hundreds of thousands of dollars in illegal kickbacks to US doctors between ...

Leading data and analytics company GlobalData’s report, Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast, ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

Gilead Sciences Inc. has divulged bridged tricyclic carbamoylpyridone prodrugs acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infection.

Gilead Sciences announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research ...

BofA Securities Health Care Conference May 13, 2025 2:20 PM ET. Company Participants. Johanna Mercier – Chief Commercial Officer. Conference ...

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.